Group Leader: Dr Heiko Wurdak
Our research aims to provide novel insight into tumour cell biology and potential drug targets in brain cancer. We are interested in elucidating the cellular heterogeneity in tumours, stem cell-like properties of cancer cells, and molecular pathways that regulate the balance between self-renewal and differentiation.
Aggressive brain tumours such as Glioblastoma multiforme are very difficult to treat due to their high complexity resulting from molecular and cellular diversity within a single tumour (intra-tumour heterogeneity), tumour heterogeneity across patients, tumour invasion (infiltration of tumour cells into the brain), and resistance to DNA-damaging therapy. Interestingly, many of these characteristics have been attributed to undifferentiated cells in brain tumours known as brain tumour stem cells (BTSCs). BTSCs that are resistant to therapy may expand from very few cells, thereby helping the cancer to reoccur after and during treatment. Therefore, eliminating BTSCs through specific therapy is a desirable goal that requires suitable molecular targets.
Our previous work has implicated several proteins such as TRRAP and TACC3 in BTSC maintenance, and importantly, clinical data also link these molecules to a poor disease outcome in brain tumour patients. Thus, we are investigating the biological role of these specific molecules in BTSCs using a spectrum of methods (e.g., RNA interference, cDNA overexpression, chemical inhibition).
At the same time, we aim to develop options for combination therapy, for example using combinations of small molecule inhibitors that render BTSCs vulnerable to treatment regimes used in clinical practice, including radiation- and oncolytic virus therapy. We are also using chemical compounds to induce differentiation in BTSCs and to study BTSC phenotypic plasticity and its implication(s) in brain tumourigeneis.
We are interested in investigating intra-tumour heterogeneity and the diversity of BTSC/non-BTSC phenotypes. To this end, we are using single cell profiling approaches that allow us to determine gene expression changes in individual cells. These approaches also allow us to study gene networks regulating self-renewal, differentiation, and malignant transformation (i.e., induced by viruses) in heterogeneous populations of normal progenitor cells, for example derived from adult liver and kidney.
Heiko Wurdak, PhD (PI/Group Leader) - email@example.com
Anjana Patel, PhD (Post-Doctoral Fellow) - firstname.lastname@example.org
Euan Polson, PhD (Post-Doctoral Fellow) - email@example.com
Verena Kuchler (PhD Student) - firstname.lastname@example.org
Jennifer Williams (Research Technician) - email@example.com
Wurdak H. (2012) Exploring the cancer stem cell phenotype with high-throughput screening applications. Future Med Chem 4 (10):1229-41.
Wurdak H., Zhu S., Min K.H., Aimone L., Lairson L.L., Watson J., Chopiuk G., Demas J., Charette B., Halder R., Weerapana E., Cravatt B.F., Cline H.T., Peters E.C., Zhang J., Walker J.R., Wu C., Chang J., Tuntland T., Cho C.Y., Schultz P.G. (2010). A small molecule accelerates neuronal differentiation in the adult rat. PNAS 107 (51):22360.
Wurdak H., Zhu S., Romero A., Lorger M., Watson J., Chiang C., Zhang J., Natu V.S., Lairson L.L., Walker J.R., Trussell C.M., Harsh G.R., Vogel H., Felding-Habermann B., Orth A.P., Miraglia L.J., Rines D.R., Skirboll S.L., Schultz P.G. (2010) An RNAi Screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 8;6(1):37-47.
Zhu S., Wurdak H., Wang J., Lyssiotis C.A., Peters E.C., Cho C.Y., Wu X., Schultz P.G. (2009) A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4 (5): 416-26.
Falk S., Wurdak H., Ittner L.M., Ille F., Sumara G., Schmid M.T., Draganova K., Lang K.S., Paratore C., Leveen P., Suter U., Karlsson S., Born W., Ricci R., Götz M., Sommer L. (2008) Brain area-specific effect of TGF-beta signaling on Wnt-dependent neural stem cell expansion. Cell Stem Cell 2 (5): 472-83.
Research in our laboratory is currently funded by the MRC (New Investigator Research Grant), AICR (Project Grant), European Commission FP7 (Marie Curie Career Integration Grant), and the Leeds CRUK centre (Development Fund).
Biomedical Health Research Centre (BHRC)
Neuro-oncology at Leeds